Vernalis PLC Vernalis + Daiichi Sankyo Enter Collaboration (1386Z)
December 13 2017 - 2:00AM
UK Regulatory
TIDMVER
RNS Number : 1386Z
Vernalis PLC
13 December 2017
13 December 2017
LSE: VER
Vernalis plc enters into research collaboration
with Daiichi Sankyo
Vernalis plc (LSE: VER) announced today that it has entered into
a drug discovery collaboration with Daiichi Sankyo Company, Limited
utilizing Vernalis' fragment and structure-based drug discovery
platform against undisclosed oncology targets.
The financial terms of this collaboration are not disclosed.
Ian Garland, CEO of Vernalis, commented: "We are delighted to be
working with Daiichi Sankyo on this project. This is another
excellent endorsement of our market leading fragment and
structure-based drug discovery platform and we look forward to a
successful collaboration with Daiichi Sankyo."
-- ends --
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014. Upon the publication of this
announcement this inside information is now considered to be in the
public domain.
Enquiries:
Vernalis plc:
Ian Garland, Chief Executive
Officer
David Mackney, Chief Financial +44 (0) 118 938
Officer 0015
Canaccord Genuity Limited (Nominated +44 (0) 20 7523
Adviser and Joint Broker) 8000
Henry Fitzgerald-O'Connor
Emma Gabriel
+44 (0) 20 7408
Shore Capital (Joint Broker): 4090
Mark Percy
Toby Gibbs
+44 (0) 20 3727
FTI Consulting: 1000
Ben Atwell
Simon Conway
Stephanie Cuthbert
Stern Investor Relations, Inc: + 1 212 362 1200
Stephanie Ascher
Jane Urheim
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage
pharmaceutical company with significant expertise in drug
development. The Group has three approved products: Tuzistra(R) XR
targeting the US prescription cough-cold market; Moxatag(R) , a
once-daily formulation of the antibiotic, amoxicillin, indicated
for the treatment of tonsillitis and/or pharyngitis secondary to
Streptococcus pyogenes in adults and pediatric patients 12 years
and older; and frovatriptan for the acute treatment of migraine. It
has an exclusive licensing agreement to develop and commercialise
multiple novel products focused on the US prescription cough-cold
market as well as eight programmes in its NCE development pipeline.
Vernalis has also significant expertise in fragment and structure
based drug discovery which it leverages to enter into
collaborations with larger pharmaceutical companies. The Company's
technologies, capabilities and products have been endorsed over the
last five years by collaborations with leading pharmaceutical
companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK,
Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit
www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that
reflect the Company's current expectations regarding future events
including the clinical development and regulatory clearance of the
Company's products, the Company's ability to find partners for the
development and commercialisation of its NCE pipeline, the
Company's ability to successfully commercialise its cough-cold
products and Moxatag(R) through its own sales force, as well as the
Company's future capital raising activities. Forward-looking
statements involve risks and uncertainties. Actual events could
differ materially from those projected herein and depend on a
number of factors including the success of the Company's research
strategies, the applicability of the discoveries made therein, the
successful and timely completion of clinical studies, the
uncertainties related to the regulatory process, the ability of the
Company to identify and agree beneficial terms with suitable
partners for the commercialisation and/or development of its
products, as well as the achievement of expected synergies from
such transactions, the acceptance of Tuzistra(R) XR, Moxatag(R) ,
frovatriptan and other products by consumers and medical
professionals, the successful integration of completed mergers and
acquisitions and achievement of expected synergies from such
transactions, and the ability of the Company to identify and
consummate suitable strategic and business combination
transactions.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFMMMZVZMGNZM
(END) Dow Jones Newswires
December 13, 2017 02:00 ET (07:00 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vernalis (LSE:VER)
Historical Stock Chart
From Apr 2023 to Apr 2024